Loading...
•
Sep 30, 2024
Vericel Q3 2024 Earnings Report
Reported a strong third quarter with significant revenue growth and profitability improvements, driven by key product performances and strategic advancements.
Key Takeaways
Vericel Corporation reported a strong third quarter in 2024, marked by a 27% increase in total revenue to $57.9 million. The company achieved a gross margin of 72% and an 84% growth in adjusted EBITDA. Key highlights include the FDA approval and commercial launch of MACI Arthro and a raised full-year profitability guidance.
Total net revenue increased by 27% to $57.9 million.
MACI net revenue grew by 19% to $44.7 million.
Burn Care net revenue increased by 66% to $13.2 million, including $12.2 million from Epicel and $1.1 million from NexoBrid.
Non-GAAP adjusted EBITDA increased by 84% to $10.0 million, representing a 17% adjusted EBITDA margin.
Vericel
Vericel
Vericel Revenue by Segment
Revenue by Segment
MACI Net Revenue
CapyFin.comEpicel Net Revenue
CapyFin.comNexoBrid Net Revenue
CapyFin.comBurn Care Net Revenue
CapyFin.com Forward Guidance
Vericel maintained total net revenue guidance of $238 to $242 million, representing 20% to 23% growth. Profitability guidance was raised to 72% gross margin and 22% adjusted EBITDA margin.
Positive Outlook
- Maintained total net revenue guidance of $238 to $242 million, or 20% to 23% growth
- Profitability guidance raised to 72% gross margin
- Profitability guidance raised to 22% adjusted EBITDA margin
Revenue & Expenses
Visualization of income flow from segment revenue to net income